Mereo BioPharma Group plc

Mereo BioPharma Group plc (MREO) shows no detected cyber incidents or red-flag 8-K filings in our 90-day monitoring window, though absence of recent signals does not indicate absence of structural risk. A biotech firm of this stage typically faces material dilution and financing runway pressures that require deeper historical context. The full $49 Report extends analysis to 12 months of filings, layers in dilution risk scoring, financing history, and AI-flagged risk signals across debt structures and equity raises. This adds the structural picture necessary to assess true downside exposure.